Recent Research Analysts’ Ratings Updates for Agilon Health (AGL)

Agilon Health (NYSE: AGL) has recently received a number of price target changes and ratings updates:

• 8/11/2026 – Agilon Health had its “overweight” rating reaffirmed by Wells Fargo & Company. They now have a $146.00 price target on the stock, up from $141.00.
• 8/10/2026 – Agilon Health was upgraded by Citigroup Inc. from “sell” to “neutral”. They now have a $115.00 price target on the stock, up from $105.00.
• 8/6/2026 – Agilon Health was given a new $116.00 price target by Robert W. Baird.
• 8/6/2026 – Agilon Health had its “buy” rating reaffirmed by Benchmark Co.. They now have a $140.00 price target on the stock, up from $95.00.
• 8/6/2026 – Agilon Health was given a new $112.00 price target by Truist Financial Corporation. They now have a “hold” rating on the stock.
• 8/6/2026 – Agilon Health was given a new $111.00 price target by Barclays PLC. They now have an “equal weight” rating on the stock.
• 7/23/2026 – Agilon Health was downgraded by Citigroup Inc. from “neutral” to “sell”. They now have a $105.00 price target on the stock, up from $80.00.
• 7/13/2026 – Agilon Health had its “overweight” rating reaffirmed by Wells Fargo & Company. They now have a $141.00 price target on the stock, up from $72.00.

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.